Beyond analysts' top -and-bottom-line estimates for Biogen (BIIB), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ...
The EC requests CHMP to reassess new safety data that emerged after the positive opinion recommending the approval of ...
Learn more about whether Biogen Inc. or Exact Sciences Corporation is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.
The FDA last month accepted the application for subcutaneous Leqembi for maintenance dosing, with a target action date of ...
Biogen Inc. closed 41.60% below its 52-week high of $246.44, which the company achieved on February 7th.
An international clinical trial aimed at preventing Alzheimer’s disease (AD) in young adults who are at risk of developing ...
Children who inherit genetic mutations from parents with early-onset Alzheimer’s typically show signs of dementia at the same ...
The European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for BAT2506 as a biosimilar to reference p ...
The Payment Card Industry Data Security Standard’s 4.0 requirements are designed to protect card information from theft or ...
Biogen (NASDAQ:BIIB) shares experienced a change in market expectations as Cantor Fitzgerald revised the company's price target. The new target has been set at $206.00, a decrease from the previous ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback